Concert Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNCE)

$21.12 -0.36 (-1.68 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$21.44
Today's Range$21.01 - $21.83
52-Week Range$9.04 - $30.71
Volume151,000 shs
Average Volume486,711 shs
Market Capitalization$489.15 million
P/E Ratio5.68
Dividend YieldN/A
Beta1.23

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Debt-to-Equity RatioN/A
Current Ratio28.18%
Quick Ratio28.18%

Price-To-Earnings

Trailing P/E Ratio5.67741935483871
Forward P/E Ratio5.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales2,828.84
Cash FlowN/A
Price / CashN/A
Book Value$3.84 per share
Price / Book5.50

Profitability

Trailing EPS$3.72
Net Income$-50,720,000.00
Net Margins62.31%
Return on Equity-51.48%
Return on Assets-42.46%

Miscellaneous

Employees69
Outstanding Shares22,770,000

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.03. The biotechnology company earned $0.07 million during the quarter, compared to analyst estimates of $0.06 million. Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%. View Concert Pharmaceuticals' Earnings History.

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2018?

4 equities research analysts have issued 1-year price targets for Concert Pharmaceuticals' stock. Their predictions range from $21.00 to $27.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $24.00 in the next twelve months. View Analyst Ratings for Concert Pharmaceuticals.

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:

  • Richard H. Aldrich, Chairman of the Board, Co-Founder (Age 62)
  • Roger D. Tung Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 57)
  • Ryan Lynch, Principal Financial Officer, Principal Accounting Officer
  • Marc Becker, Chief Financial Officer (Age 45)
  • Nancy Stuart, Chief Operating Officer (Age 55)
  • Ian Robert Silverman, Senior Vice President and General Counsel (Age 63)
  • James Cassella, , Senior Vice President, chief development officer
  • Christine Boisclair, Vice President - Regulatory Affairs
  • Scott Weintraub, Vice President - Commercial and Product Strategy
  • Thomas G. Auchincloss Jr., Director (Age 52)

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (8.65%), BlackRock Inc. (7.84%), Ingalls & Snyder LLC (5.77%), Millennium Management LLC (3.19%), Franklin Resources Inc. (2.65%) and Renaissance Technologies LLC (1.57%). Company insiders that own Concert Pharmaceuticals stock include Richard Aldrich, Roger D Tung, Ronald W Barrett, Ryan Lynch, Thomas G Auchincloss and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.

Who sold Concert Pharmaceuticals stock? Who is selling Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Lyon Street Capital LLC, Senvest Management LLC, Driehaus Capital Management LLC, Franklin Resources Inc., Senzar Asset Management LLC, Citadel Advisors LLC and First Manhattan Co.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Acadian Asset Management LLC, Bogle Investment Management L P DE, Two Sigma Investments LP, Arrowstreet Capital Limited Partnership, Ingalls & Snyder LLC and Teachers Advisors LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung, Thomas G Auchincloss and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $21.12.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $489.15 million and generates $170,000.00 in revenue each year. The biotechnology company earns $-50,720,000.00 in net income (profit) each year or $3.72 on an earnings per share basis. Concert Pharmaceuticals employs 69 workers across the globe.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Concert Pharmaceuticals (NASDAQ:CNCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.753.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.75$26.40
Price Target Upside: 20.24% upside19.11% upside40.07% upside85.65% upside

Concert Pharmaceuticals (NASDAQ:CNCE) Consensus Price Target History

Price Target History for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ:CNCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018MizuhoReiterated RatingHold$23.00LowView Rating Details
1/12/2018Stifel NicolausReiterated RatingBuy$27.00N/AView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy$21.00N/AView Rating Details
6/12/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings History and Estimates Chart

Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ CNCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.54)($0.70)$0.02 million$0.02 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.58)$0.20 million$0.02 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
3/31/2014Q4 2013($4.64)$1.41 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings Estimates

Current Year EPS Consensus Estimate: $4.1 EPS
Next Year EPS Consensus Estimate: $-2.35 EPS

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 76.61%
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018Richard AldrichDirectorSell11,946$20.89$249,551.94286,975View SEC Filing  
1/29/2018Richard AldrichDirectorSell18,054$20.63$372,454.02286,975View SEC Filing  
1/26/2018Richard AldrichDirectorSell5,000$20.46$102,300.00286,975View SEC Filing  
1/24/2018Richard AldrichDirectorSell30,000$19.68$590,400.00286,975View SEC Filing  
1/22/2018Richard AldrichDirectorSell10,000$19.55$195,500.00286,975View SEC Filing  
1/19/2018Richard AldrichDirectorSell30,000$19.35$580,500.00286,975View SEC Filing  
1/16/2018Richard AldrichDirectorSell31,236$19.14$597,857.04286,975View SEC Filing  
12/19/2017Value Fund L P BiotechnologyInsiderSell1,282,856$26.65$34,188,112.40View SEC Filing  
12/4/2017Ronald W BarrettDirectorSell14,156$24.70$349,653.203,539View SEC Filing  
10/19/2017Value Fund L P BiotechnologyInsiderBuy331,916$15.84$5,257,549.44View SEC Filing  
9/14/2017Ryan LynchInsiderSell3,500$14.51$50,785.009,500View SEC Filing  
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.002,000View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50538,965View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.6425,004View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.0010,000View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Concert Pharmaceuticals (NASDAQ CNCE) News Headlines

Source:
DateHeadline
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
finance.yahoo.com - February 21 at 8:49 AM
Concert Pharmaceuticals (CNCE) Given Hold Rating at MizuhoConcert Pharmaceuticals (CNCE) Given Hold Rating at Mizuho
www.americanbankingnews.com - February 13 at 11:58 AM
Concert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment ResearchConcert Pharmaceuticals (CNCE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 12 at 9:00 PM
Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia AreataConcert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
finance.yahoo.com - February 12 at 9:34 AM
Concert Pharmaceuticals (CNCE) Lifted to "Buy" at BidaskClubConcert Pharmaceuticals (CNCE) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - February 11 at 8:54 AM
Zacks: Analysts Anticipate Concert Pharmaceuticals Inc (CNCE) Will Announce Quarterly Sales of $8.11 MillionZacks: Analysts Anticipate Concert Pharmaceuticals Inc (CNCE) Will Announce Quarterly Sales of $8.11 Million
www.americanbankingnews.com - February 9 at 5:44 AM
 Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.18 Earnings Per Share Brokerages Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - February 7 at 5:10 AM
Zacks Investment Research Upgrades Concert Pharmaceuticals (CNCE) to HoldZacks Investment Research Upgrades Concert Pharmaceuticals (CNCE) to Hold
www.americanbankingnews.com - February 5 at 9:16 PM
Concert Pharmaceuticals Inc (CNCE) Receives Consensus Recommendation of "Hold" from AnalystsConcert Pharmaceuticals Inc (CNCE) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 3 at 5:32 PM
Concert Pharmaceuticals Inc (CNCE) Director Richard Aldrich Sells 11,946 SharesConcert Pharmaceuticals Inc (CNCE) Director Richard Aldrich Sells 11,946 Shares
www.americanbankingnews.com - February 1 at 6:28 PM
Mizuho Reiterates Hold Rating for Concert Pharmaceuticals (CNCE)Mizuho Reiterates Hold Rating for Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - February 1 at 1:30 PM
Concert Pharmaceuticals (CNCE) Stock Rating Lowered by Zacks Investment ResearchConcert Pharmaceuticals (CNCE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 30 at 8:38 PM
Richard Aldrich Sells 5,000 Shares of Concert Pharmaceuticals Inc (CNCE) StockRichard Aldrich Sells 5,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
www.americanbankingnews.com - January 29 at 6:32 PM
Richard Aldrich Sells 18,054 Shares of Concert Pharmaceuticals Inc (CNCE) StockRichard Aldrich Sells 18,054 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
www.americanbankingnews.com - January 29 at 6:32 PM
Concert Pharmaceuticals Inc (CNCE) Director Richard Aldrich Sells 10,000 SharesConcert Pharmaceuticals Inc (CNCE) Director Richard Aldrich Sells 10,000 Shares
www.americanbankingnews.com - January 24 at 7:04 PM
Insider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 30,000 Shares of StockInsider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - January 24 at 6:50 PM
$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter
www.americanbankingnews.com - January 23 at 11:52 AM
Richard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) StockRichard Aldrich Sells 30,000 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
www.americanbankingnews.com - January 19 at 9:52 PM
Insider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 31,236 Shares of StockInsider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 31,236 Shares of Stock
www.americanbankingnews.com - January 18 at 7:00 PM
Concert Pharmaceuticals Is In A Major Jam: Where To Next? - Seeking AlphaConcert Pharmaceuticals Is In A Major Jam: Where To Next? - Seeking Alpha
seekingalpha.com - January 18 at 10:57 AM
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent NewsBiotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News
finance.yahoo.com - January 17 at 9:54 AM
Concert Pharma shares hit low note on patent challenge denial - Boston Business JournalConcert Pharma shares hit low note on patent challenge denial - Boston Business Journal
www.bizjournals.com - January 16 at 4:52 PM
Concert Pharmaceuticals (CNCE) Given Buy Rating at Stifel NicolausConcert Pharmaceuticals (CNCE) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - January 13 at 8:00 PM
Concert Pharma (CNCE) Reports Patent Trial and Appeal Board Denies Petition on 335 PetitionConcert Pharma (CNCE) Reports Patent Trial and Appeal Board Denies Petition on '335 Petition
www.streetinsider.com - January 13 at 9:54 AM
Concert Pharma Drops On Patent Litigation Setback; Mizuho DowngradesConcert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades
finance.yahoo.com - January 13 at 9:54 AM
Health Care Sector Update for 01/12/2018: PSTI,GSK,CNCE,INCY - NasdaqHealth Care Sector Update for 01/12/2018: PSTI,GSK,CNCE,INCY - Nasdaq
www.nasdaq.com - January 12 at 4:43 PM
Mizuho Lowers Concert Pharmaceuticals (CNCE) to NeutralMizuho Lowers Concert Pharmaceuticals (CNCE) to Neutral
www.americanbankingnews.com - January 12 at 12:38 PM
Concert Pharmaceuticals Inc. (CNCE) Is Falling After PGR Petition DeniedConcert Pharmaceuticals Inc. (CNCE) Is Falling After PGR Petition Denied
www.nasdaq.com - January 12 at 10:03 AM
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia AreataFDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
finance.yahoo.com - January 12 at 10:03 AM
Concert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from AnalystsConcert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:44 PM
Zacks: Brokerages Anticipate Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $8.10 MillionZacks: Brokerages Anticipate Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $8.10 Million
www.americanbankingnews.com - January 6 at 4:18 AM
Concert Pharmaceuticals (CNCE) Lifted to "C+" at TheStreetConcert Pharmaceuticals (CNCE) Lifted to "C+" at TheStreet
www.americanbankingnews.com - December 30 at 4:22 PM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 5:12 PM
Concert Pharmaceuticals (CNCE) Rating Lowered to Buy at BidaskClubConcert Pharmaceuticals (CNCE) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - December 23 at 2:10 PM
Insider Selling: Concert Pharmaceuticals Inc (CNCE) Insider Sells 1,282,856 Shares of StockInsider Selling: Concert Pharmaceuticals Inc (CNCE) Insider Sells 1,282,856 Shares of Stock
www.americanbankingnews.com - December 21 at 8:28 PM
Concert Pharmaceuticals Inc. (CNCE) Has Risen To A New High After New CFO NamedConcert Pharmaceuticals Inc. (CNCE) Has Risen To A New High After New CFO Named
www.nasdaq.com - December 20 at 10:03 AM
$8.10 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter$8.10 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter
www.americanbankingnews.com - December 20 at 2:52 AM
UBS Reaffirms "Buy" Rating for Concert Pharmaceuticals (CNCE)UBS Reaffirms "Buy" Rating for Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - December 19 at 7:26 AM
Concert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per ShareConcert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - December 18 at 9:20 PM
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial OfficerConcert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
finance.yahoo.com - December 18 at 10:21 AM
Concert Pharmaceuticals Inc (CNCE) Given Average Rating of "Buy" by BrokeragesConcert Pharmaceuticals Inc (CNCE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 5:26 PM
Concert Pharmaceuticals: Materialized Income With Reasonable Valuation - Seeking AlphaConcert Pharmaceuticals: Materialized Income With Reasonable Valuation - Seeking Alpha
seekingalpha.com - December 14 at 5:25 PM
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology IndexConcert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 13 at 10:20 AM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 5:02 PM
BidaskClub Upgrades Concert Pharmaceuticals (CNCE) to Strong-BuyBidaskClub Upgrades Concert Pharmaceuticals (CNCE) to Strong-Buy
www.americanbankingnews.com - December 9 at 9:50 AM
Ronald W. Barrett Sells 14,156 Shares of Concert Pharmaceuticals Inc (CNCE) StockRonald W. Barrett Sells 14,156 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
www.americanbankingnews.com - December 6 at 5:46 PM
Concert Pharmaceuticals: Thoughts Going Into 2018 - Seeking Alpha - Seeking AlphaConcert Pharmaceuticals: Thoughts Going Into 2018 - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 5 at 10:43 AM
Concert Pharmaceuticals Inc (CNCE) Expected to Announce Quarterly Sales of $8.10 MillionConcert Pharmaceuticals Inc (CNCE) Expected to Announce Quarterly Sales of $8.10 Million
www.americanbankingnews.com - December 2 at 2:50 AM
Celldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial ContrastCelldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial Contrast
www.americanbankingnews.com - December 1 at 9:32 PM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 5:18 PM

SEC Filings

Concert Pharmaceuticals (NASDAQ:CNCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Concert Pharmaceuticals (NASDAQ:CNCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Concert Pharmaceuticals (NASDAQ CNCE) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.